Quanterix Corp. 10-Q Summary: Period Ended June 30, 2026
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for Quanterix Corporation (QTRX) for the three and six months ended June 30, 2026. Quanterix is a life sciences company focused on ultra-sensitive biomarker detection using its proprietary Simoa technology and spatial biology platforms. The company operates as a single reportable segment. Following the acquisition of Akoya Biosciences in July 2025, the company completed integration activities in Q2 2026, consolidating into a single reporting unit.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2026 | 6 Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $32,906 | $69,322 |
| Gross Profit | $12,674 | $28,241 |
| Gross Margin | 39% | 41% |
| Net Loss | $(48,934) | $(66,475) |
| Net Loss Per Share (Basic/Diluted) | $(1.04) | $(1.41) |
| Cash and Cash Equivalents | $44,169 | $44,169 |
| Marketable Securities | $49,360 | $49,360 |
| Total Liquidity (Cash + Securities) | $93,529 | $93,529 |
| Net Cash Used in Operating Activities | N/A | $(23,226) |
Note: The company reported no long-term debt as of June 30, 2026. Total liabilities were $82.4 million, primarily consisting of operating lease liabilities and accrued expenses.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 34% ($8.4 million) for the quarter and 26% ($14.5 million) for the six months compared to the prior year periods. This growth was driven by the inclusion of Akoya Biosciences, which contributed $9.3 million in product revenue and $3.0 million in service revenue for the quarter.
- Legacy Performance: Excluding Akoya, legacy Quanterix product revenue decreased $2.7 million (quarter) and $6.7 million (six months) due to weaker demand from academic and pharmaceutical customers amid constrained research funding.
- Impairment Charges: The company recorded significant non-cash impairment charges totaling $46.8 million for the six months ended June 30, 2026. This includes a $26.9 million goodwill impairment charge in Q2 2026 and a $19.3 million impairment of in-process research and development (IPR&D) in Q1 2026 related to the termination of a diagnostic development agreement.
- Operating Expenses: Research and Development (R&D) expenses decreased 14% (quarter) and 21% (six months) year-over-year, largely due to the absence of non-recurring contingent payments from the 2025 Emission acquisition. Selling, General, and Administrative (SG&A) expenses also decreased due to lower acquisition-related costs and restructuring savings.
- Other Income: Other income (expense), net increased significantly in the six-month period due to a one-time $21.9 million gain recognized from the termination of the Akoya-related Development Agreement (comprising $14.0 million from off-market liability reversal and $7.9 million from deferred revenue).
Guidance, Outlook, and Risks
- Strategic Shift: Following a new CEO appointment in January 2026, the company announced a strategy update in May and August 2026 to accelerate revenue growth in research tools and advance its position in Alzheimer's diagnostics. This includes reorganizing the commercial organization and hiring a new Chief Commercial Officer.
- Alzheimer's Diagnostics: The company submitted a 510(k) premarket notification to the FDA in January 2026 for a multi-analyte blood test for Alzheimer's disease. Additionally, the LucentAD Complete test received a Medicare reimbursement rate of $897 in November 2025, with coverage expansion to Anthem Blue Cross and Blue Shield members effective July 1, 2026.
- Cash Flow Outlook: Management revised its cash flow breakeven target from year-end 2026 to 2027. This delay is attributed to increased investments in commercial leadership, diagnostics infrastructure, and weaker-than-expected revenue in the first half of 2026.
- Risks: Key risks include the ability to achieve cash flow breakeven, continued softness in instrument sales due to capital funding constraints, and the success of the new commercial strategy. The company maintains a valuation allowance on the majority of its deferred tax assets.
Investor Verification Checklist
- Impairment Details: Verify the specific assumptions used in the quantitative goodwill impairment test and the impact of the $26.9 million charge on future earnings.
- Legacy Revenue Trends: Monitor the trajectory of legacy Quanterix revenue to confirm if the decline in academic and pharma demand is stabilizing or worsening.
- Alzheimer's Test Progress: Track the FDA review timeline for the 510(k) submission and the commercial uptake of the LucentAD Complete test following the new payer coverage.
- Cash Burn Rate: Assess the sustainability of the current cash position ($93.5 million) against the revised 2027 breakeven target and ongoing operating losses.
- Contingent Liabilities: Review the fair value changes and potential payout ranges for the Emission earnout and the PKI License contingent liabilities.